%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-07-17T12:28:02+05:30
2017-07-17T12:28:02+05:30
2017-07-17T12:28:02+05:30
Adobe InDesign CS6 (Macintosh)
uuid:ca03a9ce-3999-f14f-86e8-1f36627cd618
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:7FC2432617206811822A9B203D24B917
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2017-07-17T12:28:02+05:30
xmp.iid:5B93961A09206811822A9B203D24B917
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>
endobj
8 0 obj
<>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB]/Properties<>/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
16 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
19 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
43 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 45 51.6404 Tm
(32)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
BT
/T1_0 1 Tf
10 0 0 10 45 698.16 Tm
(76.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.163 Tw 0.58 0 Td
[(Hig)4.9(ashi )90.3(Y)128.9(, Nakamura )0.5(S, )50.3(T)79.8(omono )0.5(H, et al. )0.5([Serodiagnosis )]TJ
0.21 Tw 0 -1.2 TD
[(of the m)39.8(ycobacterium a)34.9(vium comple)14.9(x b)24.9(y using ig)4.9(a anti)]TJ
0 Tw (-)Tj
0.273 Tw T*
[(bodies for the gl)24.9(ycopeptidolipid core antigen]. K)24.9(ekkaku )]TJ
0 Tw T*
(2016;91:27-32.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(77.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.053 Tw 0.58 0 Td
[(Kitada S, Le)25(vin )54.7(A, Hiserote M, et al. Serodiagnosis of Myco)]TJ
0 Tw (-)Tj
0.124 Tw T*
[(bacterium a)34.9(vium comple)14.9(x pulmonar)-19.7(y disease in the USA. )]TJ
0 Tw T*
(Eur Respir J 2013;42:454-60.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(78.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.06 Tw 0.58 0 Td
[(T)34.9(ran )54.7(A)39.8(C, Halse )49.6(T)92.8(A, Escuy)19.8(er )49.6(VE, Musser KA. Detection of )]TJ
0.232 Tw T*
[(Mycobacterium a)34.9(vium comple)14.9(x DN)34.9(A directl)25(y in clinical )]TJ
0.351 Tw T*
[(respirator)-19.7(y specimens: oppor)-19.8(tunities for impro)44.9(v)14.9(ed tur)-19.8(n-)]TJ
0.126 Tw T*
[(around time and cost sa)35(vings. Diagn Microbiol Infect Dis )]TJ
0 Tw T*
(2014;79:43-8.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(79.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.09 Tw 0.58 0 Td
[(Shrestha )0.5(NK, )50.4(T)85(uoh)29.7(y )0.5(MJ)59.9(, )0.5(Hall )0.5(GS, )0.5(Reischl )0.6(U)79.8(, )0.5(Gordon )0.6(SM, )]TJ
-0.049 Tw T*
[(Procop GW)149.9(. Detection and dif)24.9(ferentiation of Mycobacterium )]TJ
0.141 Tw T*
[(tuberculosis and nontuberculous m)39.8(ycobacterial isolates b)24.9(y )]TJ
0 Tw T*
(real-time PCR. J Clin Microbiol 2003;41:5121-6.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(80.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.003 Tw 0.58 0 Td
[(Bainomugisa )55.2(A, )30(W)79.9(ampande E, Muchw)24.9(a C, et al. Use of real )]TJ
0.135 Tw T*
[(time pol)24.9(ymerase chain reaction for detection of M. tuber)]TJ
0 Tw 23.667 0 Td
(-)Tj
0.032 Tw -23.667 -1.2 Td
[(culosis, M. a)35(vium and M. kansasii from clinical specimens. )]TJ
0 Tw T*
(BMC Infect Dis 2015;15:181.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(81.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.09 Tw 0.58 0 Td
[(Hirama )49.7(T)99.8(, Shiono )54.7(A, Eg)4.9(ashira H, et al. PCR-Based rapid iden)]TJ
0 Tw (-)Tj
-0.02 Tw T*
[(ti\037cation )0.5(system )0.5(using )0.5(bridged nucleic )0.6(acids )0.5(for )0.5(detection )0.5(of )]TJ
0.045 Tw T*
[(clarithrom)39.8(ycin-resistant Mycobacterium a)34.9(vium-M. intracel)]TJ
0 Tw (-)Tj
T*
[(lulare comple)15(x isolates. J Clin Microbiol 2016;54:699-704.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(82.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.146 Tw 0.58 0 Td
[(T)34.9(re)14.9(glia G, )50.1(T)79.9(aralli S, Calcagni ML, Maggi F)129.8(, Giordano )55.2(A, )]TJ
-0.084 Tw T*
[(Bonomo L. Is there a role for \036uorine 18 \036uorodeo)19.7(xyglucose-)]TJ
0 Tw ( )Tj
-0.046 Tw T*
[(positron emission tomo)24.9(g)-19.8(raph)29.8(y and positron emission tomo)24.9(g)]TJ
0 Tw (-)Tj
0.34 Tw T*
[(raph)29.8(y/computed tomo)24.9(g)-19.8(raph)29.8(y in e)24.9(v)24.9(aluating patients with )]TJ
0.312 Tw T*
[(m)39.8(ycobacteriosis? )54.6(A systematic re)24.9(vie)24.9(w)89.9(. J Comput )54.5(Assist )]TJ
0 Tw T*
[(T)79.8(omo)24.9(g)-19.7(r 2011;35:387-93.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(83.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.298 Tw 0.58 0 Td
[(Demura )90.3(Y)128.9(, )50.3(Tsuchida )50.2(T)99.9(, Uesaka D)59.9(, et al. Usefulness )0.5(of )]TJ
0.62 Tw T*
[(18F-\036uorodeo)19.8(xyglucose positron emission tomo)24.9(g)-19.8(raph)29.8(y )]TJ
0.125 Tw T*
[(for diagnosing disease acti)25(vity and monitoring therapeutic )]TJ
0.027 Tw T*
[(response in patients with pulmonar)-19.7(y m)39.8(ycobacteriosis. Eur J )]TJ
0 Tw T*
(Nucl Med Mol Imaging 2009;36:632-9.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(84.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.205 Tw 0.58 0 Td
[(Y)139.9(amazaki )90.3(Y)128.9(, Danelishvili L, )30.2(W)49.8(u M, et al. )50.2(The ability to )]TJ
0.004 Tw T*
[(for)-19.8(m bio\037lm in\036uences Mycobacterium a)34.9(vium in)39.8(v)24.9(asion and )]TJ
0.209 Tw T*
(translocation of bronchial epithelial cells. Cell Microbiol )Tj
0 Tw T*
(2006;8:806-14.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(85.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.042 Tw 0.58 0 Td
[(Xu HB)29.8(, Jiang RH, Li L. )50.2(T)34.9(reatment outcomes for Mycobacte)]TJ
0 Tw (-)Tj
-0.045 Tw T*
[(rium a)34.9(vium comple)14.9(x: a systematic re)24.9(vie)25(w and meta-anal)25(ysis. )]TJ
0 Tw T*
(Eur J Clin Microbiol Infect Dis 2014;33:347-58.)Tj
/T1_0 1 Tf
26.4 49.209 Td
(86.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.188 Tw 0.58 0 Td
[(Lam PK, Grif\037th DE, )54.7(Aksamit )49.5(TR, et al. F)59.9(actors related )]TJ
0.303 Tw T*
[(to response to inter)-19.7(mittent treatment of Mycobacterium )]TJ
0.135 Tw T*
[(a)34.9(vium comple)14.9(x lung disease. )54.7(Am J Respir Crit Care Med )]TJ
0 Tw T*
(2006;173:1283-9.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(87.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.283 Tw 0.58 0 Td
[(Jeong BH, )0.5(Jeon K, )0.5(P)14.9(ark HY)128.9(, )0.5(et al. Inter)-19.7(mittent antibi)]TJ
0 Tw (-)Tj
0.413 Tw T*
[(otic therap)29.8(y for nodular bronchiectatic )0.5(Mycobacterium )]TJ
0.135 Tw T*
[(a)34.9(vium comple)14.9(x lung disease. )54.7(Am J Respir Crit Care Med )]TJ
0 Tw T*
(2015;191:96-103.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(88.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.008 Tw 0.58 0 Td
[(W)79.8(allace RJ)59.8(, Bro)39.8(wn-Elliott B)34.9(A, McNulty S, et al. Macrolide/)]TJ
0.214 Tw T*
[(azalide )0.6(therap)29.8(y )0.6(for )0.5(nodular/bronchiectatic )0.7(m)39.8(ycobacterium )]TJ
0 Tw T*
[(a)34.9(vium comple)14.9(x lung disease. Chest 2014;146:276-82.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(89.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.212 Tw 0.58 0 Td
[(K)34.9(obashi )90(Y)128.9(, Matsushima )50(T)99.8(, Oka M. )55.1(A doub)19.8(le-b)19.8(lind rand)]TJ
0 Tw (-)Tj
0.212 Tw T*
[(omized study of amino)24.9(gl)24.9(ycoside infusion with combined )]TJ
0.048 Tw T*
[(therap)29.8(y for pulmonar)-19.7(y Mycobacterium a)34.9(vium comple)14.9(x dis)]TJ
0 Tw (-)Tj
T*
(ease. Respir Med 2007;101:130-8.)Tj
/T1_0 1 Tf
0.03 Tc -0.03 Tw -1.8 -1.2 Td
(90.)Tj
/Span<>> BDC
1.31 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.115 Tw 0.49 0 Td
[(K)34.9(oh )30.2(WJ)59.8(, Jeong BH, Jeon K, et al. Response to s)19.8(witch)30( )]TJ
0.215 Tw T*
[(from inter)-19.8(mittent therap)29.8(y to dail)24.9(y therap)29.8(y for refrac)]TJ
0 Tc 0 Tw (-)Tj
0.03 Tc 0.618 Tw T*
[(tor)-19.8(y nodular bronchiectatic Mycobacterium a)34.9(vium)30( )]TJ
0.237 Tw T*
[(comple)14.9(x lung disease. )54.5(Antimicrob )54.6(Agents Chemother)30( )]TJ
-0.03 Tw T*
(2015;59:4994-6.)Tj
/T1_0 1 Tf
0.01 Tc -0.01 Tw -1.8 -1.2 Td
(91.)Tj
/Span<>> BDC
1.25 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.117 Tw 0.55 0 Td
[(Moon SM, P)14.9(ark HY)129(, Kim SY)128.9(, et al. Clinical characteris)]TJ
0 Tc 0 Tw (-)Tj
0.01 Tc 0.177 Tw T*
(tics, treatment outcomes, and resistance mutations asso)Tj
0 Tc 0 Tw (-)Tj
0.01 Tc 0.468 Tw T*
[(ciated with macrolide-resistant Mycobacterium a)34.9(vium)10( )]TJ
0.429 Tw T*
[(comple)14.9(x lung disease. )54.5(Antimicrob )54.5(Agents Chemother)10( )]TJ
-0.01 Tw T*
(2016;60:6758-65.)Tj
/T1_0 1 Tf
0.03 Tc -0.03 Tw -1.8 -1.2 Td
(92.)Tj
/Span<>> BDC
1.31 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.141 Tw 0.49 0 Td
[(Kadota )49.5(T)99.8(, Matsui H, Hirose )49.5(T)99.9(, et al. )54.6(Anal)24.9(ysis of dr)-19.8(ug)30( )]TJ
0.33 Tw T*
[(treatment outcome in clarithrom)39.8(ycin-resistant Myco)]TJ
0 Tc 0 Tw (-)Tj
0.03 Tc -0.005 Tw T*
[(bacterium a)35(vium comple)14.9(x lung disease. BMC Infect Dis)30( )]TJ
-0.03 Tw T*
(2016;16:31.)Tj
/T1_0 1 Tf
0 Tc 0 Tw -1.8 -1.2 Td
(93.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.092 Tw 0.58 0 Td
[(F)19.8(igueira Gon\347alv)14.9(es JM, Rodr\355guez Gonz\341lez )0.5(J)59.8(. Lady )30.2(W)39.8(in)]TJ
0 Tw (-)Tj
0.235 Tw T*
[(der)-19.8(mere Syndrome: does it occur onl)24.9(y in w)39.8(omen? )54.7(Arch )]TJ
0 Tw T*
(Bronconeumol 2016;52:538-9.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(94.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.063 Tw 0.58 0 Td
[(Cassidy PM, Hedber)17.9(g K, Saulson )55.2(A, McNell)24.9(y E, )30(W)39.8(inthrop )]TJ
0.559 Tw T*
[(KL. Nontuberculous m)39.8(ycobacterial disease pre)25(v)24.9(alence )]TJ
0.107 Tw T*
[(and risk f)-9.8(actors: a changing epidemiolo)24.9(gy)85(. Clin Infect Dis )]TJ
0 Tw T*
(2009;49:e124-9.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(95.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.25 Tw 0.58 0 Td
[(Mar)-29.8(ras )50.3(TK, Chedore )0.5(P)159.9(, )90.3(Y)39.8(ing )55.3(AM, )0.5(Jamieson )0.5(F)129.8(. )0.5(Isolation )]TJ
0.132 Tw T*
[(pre)24.9(v)24.9(alence of pulmonar)-19.8(y non-tuberculous m)39.8(ycobacteria in )]TJ
0 Tw T*
[(Ontario, 1997 2003. )49.8(Thorax 2007;62:661-6.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(96.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.427 Tw 0.58 0 Td
[(K)24.9(ennedy )49.6(TP)159.9(, )29.6(W)99.9(eber DJ)59.8(. Nontuberculous m)39.8(ycobacteria. )]TJ
0.095 Tw T*
[(An )0.5(underappreciated )0.6(cause )0.5(of )0.5(geriatric )0.5(lung )0.5(disease. )55.4(Am )0.5(J )]TJ
0 Tw T*
(Respir Crit Care Med 1994;149:1654-8.)Tj
ET
endstream
endobj
36 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 281.1571 54.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2017;5\(20\):22\226\
32)Tj
ET
endstream
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 45 68.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 45 740.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 751.5262 Tm
(Kumfer et al.)Tj
/Span<>> BDC
( )Tj
EMC
54.781 0 Td
[(Lady W)8.7(indermere Syndrome)]TJ
ET
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
47 0 obj
<>stream
H\j0EY&G1N^A|#SA-Y;҄*~dGQeG&!ZEUp"*8?I0`M
^dsm78k,>F>+ n!
endstream
endobj
48 0 obj
<>stream
HlU TUGYp +0 (`wDM4fT".qC.Ĉ1̨S`Ns~ݿֽA c$?w=i:r)6^S]
h#"b[ uߨlS1p_C~mc#cNɒ) gm9x9p
hgF6:{e|\B{~?~vD++x HthV3ZSgHR%
73]7}P V@ 5sd\xG~3?xS*`ai6vM6kҢe֮F7{϶^nc']wޣg}?`C>:lA=棐>[O8)L6}FL̸Y$MNO,\xIe-_r5k֥߰6Ŗ_n۞c̬_ٻO}CE=vSŧy曳_XrWZy?6|!`
X :
d .Kblm4==yn&7O0L&{hd(}&]+v4s`t24?Le?t]г"}mꌷ^VzijU)+3+WW *+gUNx֮X+n(wj$"K_|R,slC|4vA6
ϐ`->
|j ؋ZO<dLA:K2|r|H\\~DG
T:Q1
3Na1 D$a.!O)va!Ws1n
wpP[x"YgsюùaEyy^[gH8XraGf?1BXO0r1GStP!s=Upc)\,:!lY[u,ɺƧ߭|ԈH'Z瞇̕XX15xE!)G2^i*Jorέal#I\v,|I)|8neqə<-2Nz#,DXdR^l2KJ>W*Y=6X^p=ZOwSWxa27Rƶ;Ü8\9μwxdC~ԋzS$ŰS+T!Ƌp)ʥ
j
V swsn/u+ccfbVzlp َ333_9RsjCȇ|ɟiR%R
-4J-RgSL.=ga$A(\ƳLV+U^ZruE^kZQBj0
цM;bEK,[2X|wc^bTRt(Xd#0C~I״X)z4R4R%C7J&ov$+i!-S{T%
%#8G%qϋ]$C8Ldsf3V""]ih}mSgi~{RPGYZER^Z""
vXL"H#VIp=h22H,ݠMAZ4ZAS=}I2GVPBd4g,P 5P7T2ͤ!WjS]Տ覗smSάٌ5qȅ%yӘMYʇp ( 3DӻWݻuٯSG>oӣںU.N͛5uthbogkWklwIL6!$v'űȆ YEUhKyЪjU[ ZAW`]ղP+kGZj4{$dITg=={l⍜ bL˙
[ -3MfM,bf$H/drCb%ZbZ}X#CYo9Q+xPL@'@HӮ>Q1eOB